{"url":"https://newsforagent.com/news/2026-10-19/full-life-fl-261-imaging-data-nsclc","markdown_url":"https://newsforagent.com/news/2026-10-19/full-life-fl-261-imaging-data-nsclc.md","title":"Full-Life FL-261 Imaging Data Shows Tumor Uptake in 10 Patients","headline":"Full-Life Technologies Reports First-in-Human FL-261 Imaging Data in 10 NSCLC Patients","description":"Full-Life Technologies reported first-in-human FL-261 imaging data in 10 NSCLC patients, with no tracer-related serious adverse events and tumor uptake rising with c-MET expression.","section":"Research & Clinical Trials","published_at":"2026-10-19T15:02:54+00:00","modified_at":"2026-10-19T15:02:54+00:00","author":"News Desk","key_takeaways":["Full-Life Technologies presented first-in-human [111In]In-FL-261 imaging data in 10 patients with non-small cell lung cancer at the EANM Congress. Tumor SUVmax reached 43.2 at 72 hours in a patient with a high c-MET IHC score, and no tracer-related serious adverse events were reported. The FDA cleared the IND for [225Ac]Ac-FL-261 in September 2026, alongside regulatory clearances in Australia and China."],"companies":[{"name":"Full-Life Technologies","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00003ft/full-life-technologies","website":"https://www.full-life.com"}],"source":{"publisher":"PR Newswire","title":"Full-Life Technologies Reports First-in-Human Imaging Data for c-MET-Targeting Theranostic Ligand FL-261 Showing Robust Tumor Uptake, High Lesion Contrast and No Tracer-Related Serious Adverse Events ","url":"https://www.prnewswire.com/news-releases/full-life-technologies-reports-first-in-human-imaging-data-for-c-met-targeting-theranostic-ligand-fl-261-showing-robust-tumor-uptake-high-lesion-contrast-and-no-tracer-related-serious-adverse-events-in-patients-with-nsclc-302912663.html"},"other_sources":[],"tags":["Research & Clinical Trials","Full-Life Technologies"],"body_markdown":"[Full-Life Technologies](https://akta.pro/company-profiles/00003ft/full-life-technologies) reported first-in-human imaging data for [111In]In-FL-261, its c-MET-targeted theranostic radionuclide drug conjugate, in 10 patients with non-small cell lung cancer, with no tracer-related serious adverse events and tumor uptake that rose with c-MET expression. The data were presented as a Top Rated Oral Presentation at the 39th Annual Congress of the European Association of Nuclear Medicine, [PR Newswire](https://www.prnewswire.com/news-releases/full-life-technologies-reports-first-in-human-imaging-data-for-c-met-targeting-theranostic-ligand-fl-261-showing-robust-tumor-uptake-high-lesion-contrast-and-no-tracer-related-serious-adverse-events-in-patients-with-nsclc-302912663.html) reported.\n\n## What the FL-261 Imaging Trial Found\n\nThe prospective trial of [111In]In-FL-261 enrolled 10 patients with histologically confirmed NSCLC and was designed to evaluate safety, biodistribution and diagnostic performance. Patients underwent SPECT/CT imaging 4, 24 and 72 hours after injection, with a baseline [18F]FDG PET/CT for comparison. Mean patient age was 65.3 years, with a range of 59 to 71, and nine of the 10 patients were male. Histology was adenocarcinoma in five patients, squamous cell carcinoma in four and NSCLC not otherwise specified in one.\n\nTumor SUVmax at 4, 24 and 72 hours was 13.8, 25.7 and 43.2 for a patient with a high c-MET immunohistochemistry score, and 12.7, 22.9 and 20.7 for a patient with a moderate score. Across six patients with available c-MET IHC scores, [111In]In-FL-261 uptake in lesions showed a positive trend with c-MET expression, with a Spearman rho of 0.82 and a P value of 0.034, while [18F]FDG uptake did not, at rho -0.13 and P = 0.80.\n\n\"We are excited to share, for the first time, clinical imaging data showing FL-261's potential for patients with c-MET-expressing NSCLC,\" said Debora Barton, MD, Chief Medical Officer of Full-Life Technologies. \"These data demonstrate compelling FL-261 uptake in lesions with high contrast, no tracer-related serious adverse events and uptake that rose with c-MET expression in the patients studied, with favorable tumor to normal tissue ratios.\"\n\n## Full-Life's Funding and Leadership Record\n\nFull-Life Technologies is a clinical-stage radiotherapeutics company developing alpha- and beta-emitting radiopharmaceutical conjugates for solid tumors, according to akta.pro [company records](https://akta.pro/company-data). The company closed a $150 million Series D financing round in May 2026 led by Vivo Capital, bringing total funding to approximately $200 million and supporting pipeline and manufacturing buildout. Full-Life appointed Debora Barton as Chief Medical Officer in May 2025, bringing prior Lutathera (Lu-177) radiopharmaceutical development experience from AAA/Novartis to the lead clinical program.\n\n## Regulatory Clearances Behind the SumMET Trial\n\nIn September 2026, Full-Life announced that the U.S. Food and Drug Administration had cleared the Investigational New Drug application for [225Ac]Ac-FL-261, and that the program had also received regulatory clearances in Australia and China, PR Newswire APAC reported. The clearances allow the Phase 1 SumMET trial of [225Ac]Ac-FL-261 to proceed at sites in these countries for patients with non-squamous NSCLC that expresses c-MET. In May 2026, Full-Life announced the completion of a US$150 million financing package, comprising approximately US$110 million in Series D equity and US$40 million in debt, led by Vivo Capital with participation from strategic partner SK Biopharmaceuticals and multiple other investors, Pulse 2.0 reported.\n\n## Presentation Schedule at EANM\n\nThe Top Rated Oral Presentation, OP-442, is scheduled for October 19, 2026, from 16:10 to 16:20 in Hall C. Full-Life is also presenting E-Poster #0035, on the development of FL-261 as a theranostic RDC vector, during the EANM Congress, which runs October 17 to 21, 2026, in Vienna, Austria.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}